| Market Cap | ₹14,886Cr | 
| ROE | 24.79% | 
| P/E Ratio(TTM) | 8.78 | 
| EPS(TTM) | 94.65 | 
| P/B Ratio | 1.96 | 
| Dividend Yield | 0.72% | 
| Industry P/E | 34.63 | 
| Book Value | 424.71 | 
| Debt to Equity | 0.04 | 
| Face Value | 2 | 
| Parent Organisation | Natco Pharma Limited | 
| Managing Director | Shri. V. Nannapaneni | 
| NSE Symbol | NATCOPHARM | 
| FUND NAME | AUM(%) | 
|---|---|
| Sundaram Small Cap Fund Direct Growth | 1.34% | 
| Axis Nifty Smallcap 50 Index Fund Direct Growth | 0.98% | 
| Tata Small Cap Fund Direct Growth | 0.38% | 
| COMPANY | 52 WEEK  | MARKET PRICE | P/E Ratio  | |
|---|---|---|---|---|
| Cohance Lifesciences | NA (0.00%)  | 86.40  | ||
| JB Chemicals & Pharmaceuticals | NA (0.00%)  | 39.18  | ||
| Emcure Pharmaceuticals | NA (0.00%)  | 32.65  | ||
| Wockhardt | NA (0.00%)  | -450.62  |